Scholar Rock Holding SRRK
NASDAQ SRRK
$55.36 -0.58 (-1.04%)
As of: Sep 4, 2026 · 2:41 PM EDT

Scholar Rock Holding (SRRK) Income towards Parent Company (2017 - 2026)

Scholar Rock Holding (SRRK) posted quarterly Income towards Parent Company of -$101.4 million for Q1 2026, down 35.42% year-over-year from -$157.1 million in Q1 2025, and down 11.21% quarter-over-quarter from -$91.2 million in Q4 2025.

Analysis

Scholar Rock Holding (SRRK) Income towards Parent Company (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.

  • In Q1 2026, Income towards Parent Company fell 35.42% year-over-year to -$101.4 million; the TTM figure through Mar 2026 stood at -$717.0 million (down 168.23% YoY), while the FY2025 annual figure was -$377.7 million, down 53.37% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at -$101.4 million, down from -$91.2 million in the prior quarter.
  • The five-year high for Income towards Parent Company was -$9.2 million in Q1 2022, with the low at -$263.8 million in Q2 2025.
  • The 5-year median for Income towards Parent Company is -$56.8 million (2024), against an average of -$80.3 million.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company soared 93.69% in 2022, then plunged 383.1% in 2023.
  • Scholar Rock Holding's Income towards Parent Company stood at -$42.1 million in 2022, then slipped by 18.84% to -$50.0 million in 2023, then sank by 32.75% to -$66.4 million in 2024, then sank by 37.37% to -$91.2 million in 2025, then declined by 11.21% to -$101.4 million in 2026.
  • Business Quant data shows SRRK's Income towards Parent Company at -$101.4 million in Q1 2026, -$91.2 million in Q4 2025, and -$260.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 Scholar Rock Holding 7.24 Bn 7.24 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -109.33 Mn
Mar 31, 2026 -101.38 Mn
Dec 31, 2025 -90.90 Mn
Sep 30, 2025 -102.15 Mn
Jun 30, 2025 -109.90 Mn
Mar 31, 2025 -74.68 Mn
Dec 31, 2024 -66.44 Mn
Sep 30, 2024 -64.44 Mn
Jun 30, 2024 -58.49 Mn
Mar 31, 2024 -56.83 Mn
Dec 31, 2023 -48.03 Mn
Sep 30, 2023 -43.67 Mn
Jun 30, 2023 -39.08 Mn
Mar 31, 2023 -40.51 Mn
Dec 31, 2022 -40.43 Mn
Sep 30, 2022 -43.86 Mn
Jun 30, 2022 -43.15 Mn
Mar 31, 2022 -6.93 Mn
Dec 31, 2021 -35.36 Mn
Sep 30, 2021 -37.08 Mn